CI-IB-MECA Enhances TRAIL-Induced Apoptosis via the Modulation of NF-κB Signalling Pathway in Thyroid Cancer Cells

被引:39
作者
Morello, Silvana [1 ]
Sorrentino, Rosalinda [1 ]
Porta, Amalia [1 ]
Forte, Giovanni [1 ]
Popolo, Ada [1 ]
Petrella, Antonello [1 ]
Pinto, Aldo [1 ]
机构
[1] Univ Salerno, Dept Pharmaceut Sci, I-84084 Salerno, Italy
关键词
A(3) ADENOSINE RECEPTOR; TUMORICIDAL ACTIVITY; TUMOR; LIGAND; DEATH; EXPRESSION; CHEMOTHERAPY; MECHANISMS; PROLIFERATION; KINASE;
D O I
10.1002/jcp.21863
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Apoptosis is an endogenous process that can be a useful anti-cancer tool. This study aimed to investigate the effect of CI-IB-MECA, adenosine receptor A3 agonist, on TRAIL-induced apoptosis of thyroid carcinoma cells. CI-IB-MECA enhanced TRAIL-mediated apoptosis in FRO but not in ARO cells. This effect was correlated to higher expression levels of DR5 on FRO than ARO cells, that instead presented higher levels of decoy receptors, DcR1 and DcR2. To understand the cross-talk between the effect of CI-IB-MECA and TRAIL, we evaluated the nuclear translocation of p65 and c-Rel. Since the dependency by NF-kappa B, TRAIL promoted the nuclear translocation of both p65 and c-Rel subunits. However, the addition of CI-IB-MECA led to the predominant translocation of c-Rel after TRAIL addition. Furthermore, Bcl-2, cFLIP and pAkt were lower induced than caspase-3 and -9 in FRO cells. To discriminate a specific effect of TRAIL, we used tumour necrosis factor-alpha (TNF-alpha) with CI-IB-MECA. In this case, no synergism was observed. In addition, the effect of CI-IB-MECA was not A3 receptor-dependent since its antagonists, MRS1191 and FA385, failed to block CI-IB-MECA activity on TRAIL-treated FRO cells. In conclusion, CI-IB-MECA enhanced TRAIL-mediated apoptosis via NF-kappa B/c-Rel activation and DR5-dependent manner. This study may shed light on a potential drug cocktail that may prove useful as anti-cancer in an in vivo animal model. J. Cell. Physiol. 221: 378-386, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:378 / 386
页数:9
相关论文
共 44 条
[1]   HIGH-LEVELS OF C-REL EXPRESSION ARE ASSOCIATED WITH PROGRAMMED CELL-DEATH IN THE DEVELOPING AVIAN EMBRYO AND IN BONE-MARROW CELLS IN-VITRO [J].
ABBADIE, C ;
KABRUN, N ;
BOUALI, F ;
SMARDOVA, J ;
STEHELIN, D ;
VANDENBUNDER, B ;
ENRIETTO, PJ .
CELL, 1993, 75 (05) :899-912
[2]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   Predominant Bcl-XL knockdown disables antiapoptotic mechanisms:: Tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro [J].
Bai, JR ;
Sui, JH ;
Demirjian, A ;
Vollmer, CM ;
Marasco, W ;
Callery, MP .
CANCER RESEARCH, 2005, 65 (06) :2344-2352
[5]   Thyroid disease classification [J].
Bartolazzi, A ;
Gasbarri, A .
LANCET, 2000, 356 (9246) :2010-2010
[6]   The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL [J].
Chen, CL ;
Edelstein, LC ;
Gélinas, C .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2687-2695
[7]  
Chen XF, 2003, CANCER RES, V63, P1059
[8]   1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists:: Synthesis, pharmacological, and ligand-receptor modeling studies [J].
Colotta, V ;
Catarzi, D ;
Varano, F ;
Calabri, FR ;
Lenzi, O ;
Filacchioni, G ;
Martini, C ;
Trincavelli, L ;
Deflorian, F ;
Moro, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3580-3590
[9]   An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB [J].
Fishman, P ;
Bar-Yehuda, S ;
Ohana, G ;
Barer, F ;
Ochaion, A ;
Erlanger, A ;
Madi, L .
ONCOGENE, 2004, 23 (14) :2465-2471
[10]  
Fishman P, 2003, ANTICANCER RES, V23, P2077